Soluble transferrin receptors (sTfR) were detected in culture supernatants of activated human peripheral blood mononuclear cells (PBMC) using a sandwich ELISA technique with two non-crossreacting TfR MoAbs. Mitogenic stimulation of lymphoid cells induced both up-regulation of TfR surface density and release of sTfR to the medium. Peak levels of sTfR in culture supernatants occurred at day 4 after activation, 1 day later than maximum expression of TfR in the plasma membrane. Production of sTfR was independent of proliferation, as demonstrated by measuring sTfR release by PBMC, which had been irradiated with a dose of 20 Gy before activation. In addition to these in vitro experiments, we tested the sera of 85 patients with systemic lupus erythematosus (SLE), an autoimmune disease accompanied by in vivo activation of lymphocytes, for their sTfR levels. No correlation of these data was detectable to serum concentrations of the soluble a-chain of the IL-2 receptor, an unequivocal marker of lymphocyte activation. However, they correlated negatively to the haemoglobin content of the patients' erythrocytes, indicating that erythroid progenitors are the predominant source of sTfR in SLE patients' sera.
INTRODUCTION
The human transferrin receptor (TfR) is a transmembrane glycoprotein composed of two identical disulphide-linked monomers with a molecular weight of 90-95 kD each [1, 2] . The main function of this cell surface molecule is binding of the iron transport protein transferrin and delivering iron ions to the cytoplasm via endocytosis [3] . TfR surface expression is regulated by two distinct mechanisms, which depend on the growth rate of the cells and their requirements for iron, respectively [4] . Therefore, the highest numbers of TfR molecules are found on erythroid precursor cells, placental trophoblast membranes, and on most proliferating cells.
During recent years, an increasing number of reports have described a soluble form of this molecule (sTfR) detectable in serum and plasma [5] [6] [7] [8] [9] . The majority of sTfR is apparently produced by erythroid precursor cells of the red bone marrow, because there is a good correlation of sTfR serum concentrations and the function and activity of the red bone marrow in a number of haematological disorders. Elevated levels of sTfR have been described in iron deficiency anaemia, haemolytic Correspondence: Walter Woith, Institut fur Klinische Immunologie und Rheumatologie, Krankenhausstr. 12, W-8520 Erlangen, Germany. D. I. D. present address: Division Immunopathology, IIrd Medical Clinic, University of Medicine and Pharmacy, 3400 Cluji, Romania. anaemia and polycythaemia vera, decreased levels in aplastic anaemia and renal anaemia.
In addition, the TfR is a well characterized activation marker (CD7 1) for lymphocytes, which is not present on resting cells, but gets expressed after antigenic, allogenic or mitogeninduced stimulation together with the a-chain of the IL-2 receptor (CD25) and class II MHC antigens [10] . The fact that many lymphocyte membrane proteins are now known to exist also in soluble forms prompted us to examine whether this is also the case for TfR.
This study describes the characteristics of sTfR release during lymphocyte activation. Using a sandwich ELISA technique with two MoAbs against the human TfR, which react with different epitopes of their target molecule, and a standard TfR preparation from human placenta, the kinetics of this release could be quantified. Furthermore, elevated serum levels of sTfR are demonstrated in one third of patients with systemic lupus erythematosus (SLE), a disease characterized by lymphocyte activation in vivo. The origin of sTfR in these patients is discussed.
MATERIALS AND METHODS Cell culture
Peripheral blood mononuclear cells (PBMC) were prepared from normal heparinized venous blood by Lymphoprep 537 (Nycomed, Oslo, Norway) gradient centrifugation. PBMC, hybridoma cell lines, and HUT 78, a human T cell lymphoma, provided by Dr A. Weiss (San Francisco, CA), were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 5 U/ ml penicillin/streptomycin, 4 mM L-glutamine (all from GIBCO, Eggenstein, Germany), and 150 mm HEPES (Roth, Karlsruhe, Germany) at 370C, 6% CO2. PBMC were stimulated at a concentration of 5 x 105/ml by addition of 1-0 pg phytohaemagglutinin (PHA) (Wellcome, Beckenham, UK) per 1 ml medium for indicated periods of time.
Monoclonal antibodies and FACS analysis
The IgGI antibodies OKT9, 5E9 (both from ATCC, Rockville, MD), and J64 [11] were affinity purified from conditioned media. 42/6 (IgA), Tu67 (IgGI), FGI/6 (IgGl), and TH-69 (IgGI, directed against human CD7) were kindly provided by Dr I. S. Trowbridge (San Diego, CA), Dr A. Ziegler (Berlin, Germany), Dr. M. Fresno (Madrid, Spain), and Dr. M. Gramatzki (Erlangen, Germany), respectively. FACS data were obtained using an EPICS Profile I (Coulter, Hialeah, FL). TfR was stained with OKT9 (see above), and CD25 was stained with B1.49.9 from Dianova-Immunotech, Hamburg, Germany. Both were detected with dichlorotriazinyl amino fluorescein-labelled polyclonal (Fab')2 fragments of goat anti-mouse IgG and IgM from Jackson Immuno Research Laboratories, West Grove, PA.
Detergent solubilization of cells Cells were harvested by centrifugation, washed twice with PBS, and resuspended in 1 ml of 1% Triton X-100 (Fluka, Neu-Ulm, Germany) in PBS. The lysates were occasionally mixed during 1 h at 4°C and then centrifuged (24000 g, 10 min, 4°C). The resulting supernatants could be stored at 4°C for 1 week without any change of ELISA reactivity.
Quantitative determination of solubilized TfR sTfR concentrations were determined by an ELISA system based on the protocol described by Flowers et al. [7] with some modifications. The wells of ELISA plates (Maxisorp; Nunc, Roskilde, Denmark) were coated overnight with 100 pl OKT9 (2 ug/ml in 50 mm carbonate buffer, pH 9 6) . This and all subsequent incubation steps were carried out at room temperature, each followed by washing three times with PBS containing 0 05% Tween 20 (PBS-Tween). Free binding sites were then blocked for 30 min with 0 5% bovine serum albumin (BSA; Sigma, Munich, Germany) in the same buffer. Appropriately diluted samples and standard (100 p1 in PBS-Tween) were added. After 90 min, 100 p1 of 2 yg/ml biotinylated J64 in PBS-Tween were added to the wells and left for 30 min (biotinylation was performed according to Guesdon et al. [12] ). Then the plates were incubated for 30 min with 100 p1 of a 1:2000 dilution of streptavidin-biotinylated horseradish peroxidase complex (Amersham-Buchler, Braunschweig, Germany) in PBS-Tween for another 30 min. Colour development was performed using ophenylenediamine (1 mg/ml in 150 mm citrate-phosphate buffer, pH 5 0, containing 0-01% H202) as substrate. After 15 min the reaction was stopped with 100 pl 1 M HC1. Absorbance at 492 nm versus 630 nm was determined on a microplate reader (Titertek Multiskan Plus; Labsystems, Helsinki, Finland). dize this ELISA. TfR was isolated following the affinity purification protocol published by Turkewitz et al. [13] with minor modifications. The purity of the product was confirmed by SDS-PAGE according to Laemmli [14] using 7-5% polyacrylamide gels in an electrophoretic cell model 2001 (LKB-Pharmacia, Freiburg, Germany) and its identity proven by immunoblot with OKT9. Analysis of protein content was performed using a bicinchoninic acid assay (Pierce, Munich, Germany) according to the manufacturer's instructions by comparison with standard solutions of BSA.
Purification of a TfR standard

Patients and controls
The sTfR concentrations of the sera of 85 SLE patients (according to the revised ARA-criteria of 1982 [15] ) from our out-patient clinic in various stages of the disease were determined by ELISA. Twenty healthy donors served as normal controls and sera of 12 patients with iron-deficiency anaemia were used as positive controls, since this disorder is known to be accompanied by elevated serum-sTfR levels [6, 7] . Sera were stored in aliquots at -20°C and used only once. The SLE patients' sera were also tested for the content of circulating achain of the IL-2 receptor (sIL-2R) using an ELISA purchased from T Cell Diagnostics, Cambridge, MA.
RESULTS
An ELISA system for the detection of TfR solubilized from a human T lymphoma line and peripheral blood lymphocytes A sandwich ELISA system with two MoAbs against the human TfR (OKT9 coupled to plastic wells and biotinylated J64) was used to measure the amounts of TfR that could be solubilized by detergent from membranes of a T cell line, HUT 78, resting, and mitogen-stimulated lymphocytes. In contrast to unstimulated cells, the lysates of activated lymphocytes clearly show TfR reactivity in this ELISA. The content of TfR in lysates from HUT 78 is about eight times higher than that in the lysates of the same number of activated peripheral blood lymphocytes, due to higher TfR expression and larger size of HUT 78 cells (Fig. 1 ). Sequential preadsorption of samples with solid phase cou-r, 1-411--- TfR ELISA with HUT 78 lysates was performed as described, but the wells were incubated for 30 min with native TfR MoAbs in indicated concentrations before treatment with J64-biotin. The resulting optical density was measured and expressed as the percentage of binding of biotinylated J64 in control experiments without pretreatment with native antibodies. The results are means of triplicates of one representative out of three independent experiments. pled OKT9 antibodies reduced reactivity in this assay by more than 70%, whereas treatment with an isotype control solidphase antibody (TH-69) had no inhibiting effect ( < 1% reduction).
To test further the specificity of this ELISA, inhibition experiments using a panel of other MoAbs against the human TfR were performed. The competing MoAbs were added to the system before incubation with biotinylated J64. As shown in Table I , addition of native J64 completely inhibited the binding of biotinylated J64, whereas other IgGl isotype MoAbs had no or only marginal inhibitory effects. The same is true for 42/6, an IgA MoAb, reactive with the transferrin binding site. 5E9 was the only MoAb which could partially block binding of J64biotin. Therefore 5E9 either reacts with a TfR epitope closely related to that recognized by J64, or binds to the same epitope as J64 with a lower affinity.
Quantification of sTfR concentrations with a TfR standard preparation from human placental tissue TfR from human placenta was isolated according to the affinity chromatography protocol published by Turkewitz et al. [13] with minor modifications. The purity of the product was verified by SDS-PAGE and found to be more than 90%. A single band at 190 kD appeared under non-reducing conditions. The reduced sample showed one double-band at 95 kD after staining with coomassie brilliant blue (not shown). These proteins reacted positive with OKT9 in Western blot (not shown). After determination of its protein content, this extract was used as a standard preparation for our TfR ELISA system, which detects (s)TfR concentrations down to 2 ng/ml. sTfR in culture supernatants of PBMC Human PBMC at a concentration of 5 x 105/ml were stimulated by 1-0 ,ug/ml PHA. The (s)TfR content of culture supernatants and cell lysates was monitored by ELISA over 4 days in culture. TfR concentrations in lysates reached a plateau at day 3, while peak levels of sTfR in supernatants occurred 1 day later (Fig. 2) . As demonstrated by repeated freezing and thawing of activated PBMC, disruption of cell membranes led to higher TfR levels in supernatants ( Table 2 ). Thus the portion of TfR in culture supernatants which did not present a real soluble form of the receptor, but was still imbedded in membrane vesicles, probably derived from dead cells, had to be determined. Passage of supernatants through a sterile filter (0-2 um pore size) before measuring had almost no influence on their sTfR contents. The sTfR in sera ofpatients with SLE In addition, we investigated the sTfR concentrations in the sera of patients with SLE, a disease in which in vivo activation of lymphocytes occurs (Fig. 3 ). Forty-one of 85 SLE patients had elevated serum sTfR levels of more than mean +3 s.d. of a healthy control population. When SLE patients were divided in subgroups according to disease activity [16] or expression of activation markers (CD25, TfR) on PBMC, patients with higher percentages of activated circulating PBMC or an active disease also tended to have higher serum sTfR levels, but this difference did not reach statistical significance (Table 3 ). There was a weak significance in the higher serum sTfR levels of the group of patients with elevated sIL2-R concentrations, but a clear correlation between these two parameters was missing. The best correlation (P < 0-005), however, could be demonstrated between serum 4) . This is probably due to the fact that activated lymphocytes may contribute to some of the circulating sTfR, but activated erythroid precursor cells in the bone marrow account for the major portion of serum sTfR in patients with SLE and anaemia of chronic disease.
DISCUSSION
During the last decade several reports were published on origin, biochemical characterization, and clinical implication of sTfR. Most of the early cellular results were based upon experiments on reticulocytes or the promyelocytic line HL60 [17] [18] [19] [20] [21] .
In 1983, Pan and Johnstone demonstrated that sheep reticulocytes externalize vesicles containing TfR molecules during maturation in vitro [18] . These exosomes were found in vivo in the blood of anaemic (and in lower numbers in normal) animals of several species [19] . They seem to be one source of sTfR, since isolated vesicles shed a real soluble form of TfR to the medium [20] . However, only 35% of sTfR derived from reticulocytes after a 44-h incubation represent soluble protein molecules, while the rest remains embedded in vesicular membranes. We could show that sTfR produced by lymphocytes exists for the most part in a virtually soluble form. Passage of PBMC culture supernatants at day 4 after stimulation through a 02-pm sterile filter had no influence on the sTfR concentration of this filtrate, and ultracentrifugation reduced the values only to two thirds of untreated control levels. This discrepancy may be due to the longer culture times we had to use in our experiments with PBMC (4 days versus 44 h) because activation of the cells is necessary to reach detectable concentrations of sTfR in culture supernatants. If activated PBMC use the same way of shedding sTfR as reticulocytes, proteolytic activity might lead to release of sTfR from cell membrane-derived vesicles, which is then no longer removable from supernatants by ultrafiltration or ultracentrifugation. Another conceivable explanation lies in the possibility that different cells might use different ways of shedding sTfR. This hypothesis is supported by the contradictory biochemical data published on sTfR [5, [20] [21] [22] [23] [24] .
The excellent correlation of sTfR serum concentrations to erythron activity as demonstrated by elevated levels in haematological disorders with activated erythropoiesis and decreased levels in aplastic anaemia indicates that most of the sTfR circulating in sera is derived from cells of the red bone marrow [8, 9, 25, 26] . However, the fact that the receptor level drops only to about 50% of normal even in severe aplastic anaemia implies that the erythroid marrow accounts for only about one-half of the circulating sTfR [8] . So there is evidence for the existence of other sources of sTfR. Our present study addressed the question, whether activated lymphocytes could be responsible for some portion of sTfR in mammalian blood.
It could be demonstrated that there is no release of sTfR by resting PBMC in vitro. Mitogenic activation, however, not only leads to up-regulation of TfR surface density, but in parallel results in measurable concentrations of sTfR in the surrounding medium.
To determine if this sTfR production by lymphocytes is also detectable in vivo, we tested sTfR levels in the sera of 85 patients with SLE, a disease accompanied by high inflammatory activity. Nearly one half of these patients had clearly elevated serum receptor concentrations. Looking for the origin of this phenomenon, we in parallel measured the concentration of sIL-2R, a well characterized marker of activated lymphocytes [27] , in these sera. However, no correlation existed between these two parameters. On the other hand, a clear inverse correlation of sTfR to haemoglobin levels could be demonstrated in these patients. This probably indicates that not activated lymphocytes but erythroid precursor cells account for most sTfR in sera of patients with SLE due to anaemia of chronic disease.
A recent report by Ferguson et al. [28] suggested that sTfR might be useful as a criterion of differentiation between anaemia of chronic disease and iron-deficiency anaemia. In contrast, the results obtained in our group of SLE patients show that elevated serum sTfR can also be found in anaemia of chronic disease, although the levels are considerably lower than those seen in severe iron deficiency anaemia (Fig. 3) .
Nevertheless, the demonstrated sTfR production by stimulated lymphocytes could still be of value for identifying lymphocyte activation in vivo, especially in compartments where sTfR originating from bone marrow does not play a role, for example in synovial fluid. For this purpose, we are currently investigating synovial fluid and cells for the content and production of sTfR. Therefore, sTfR may be a helpful marker not only in haematological disorders, even though its molecular characteristics, physiological function, and mechanism(s) of production are still in dispute.
